Search results for "Haploidentical transplantation"

showing 5 items of 5 documents

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Trans…

2020

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo…

Adultmedicine.medical_specialtyendocrine systemHematologic malignancyTransplantation ConditioningHaploidentical transplantationGraft vs Host DiseaseContext (language use)ThioTEPAGastroenterologyMAC Regimen03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCumulative incidenceProspective StudiesTransplantationAllogeneic stem cell transplantation clinical trial Alternative donor transplantation Haploidentical transplantation Hematologic malignancy Umbilical cord blood transplantationUmbilical cord blood transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyAlternative donor transplantationFludarabineTransplantationRegimenAllogeneic stem cell transplantation clinical trialsurgical procedures operative030220 oncology & carcinogenesisHematologic NeoplasmsCord Blood Stem Cell TransplantationNeoplasm Recurrence LocalbusinessBusulfan030215 immunologymedicine.drug
researchProduct

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

2021

Abstract Introduction/Background: The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. Patients and Methods: We identified 84 ALL patients 70 to 84 years old allografted In 2002 to 2019 from a matched related (23%), unrelated (58%), haploidentical (17%), or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. Results: The 2-year relapse incide…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTransplantation ConditioningHaploidentical transplantationGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/CancerGraft-versus-host diseaseInternal medicinemedicineHumansTransplantation HomologousComplete remissionComputingMilieux_MISCELLANEOUSAgedRetrospective StudiesAged 80 and overUnivariate analysisCMV positivitybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyTotal body irradiationPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMinimal residual diseaseAllogeneic stem cell transplantationTransplantationLeukemia Myeloid AcuteGraft-versus-host diseaseOncologyTreatment-related mortalityAllogeneic stem cell transplantation; CMV positivity; Complete remission; Graft-versus-host disease; Haploidentical transplantation; Treatment-related mortalitybusiness
researchProduct

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias

2018

γδ T lymphocytes are potent effector cells, capable of efficiently killing tumor and leukemia cells. Their activation is mediated by γδ T-cell receptor (TCR) and by activating receptors shared with NK cells (e.g., NKG2D and DNAM-1). γδ T-cell triggering occurs upon interaction with specific ligands, including phosphoantigens (for Vγ9Vδ2 TCR), MICA-B and UL16 binding protein (for NKG2D), and PVR and Nectin-2 (for DNAM-1). They also respond to cytokines undergoing proliferation and release of cytokines/chemokines. Although at the genomic level γδ T-cells have the potential of an extraordinary TCR diversification, in tissues they display a restricted repertoire. Recent studies have identified …

lcsh:Immunologic diseases. Allergy0301 basic medicineαβ T-cellChemokineB-cell depletion; hematopoietic stem cells; HLA-haploidentical transplantation; receptors; αβ T-cell; γδ T-cellsReceptors Antigen T-Cell alpha-betaMini ReviewHLA-haploidentical transplantationImmunologyGenes MHC Class Ichemical and pharmacologic phenomenaMajor histocompatibility complexCD19Mice03 medical and health sciencesγδ T-cellsAntigenReceptorsMHC class ImedicineAnimalsHumansImmunology and AllergyIntraepithelial LymphocytesB-LymphocytesLeukemiaB-cell depletionbiologyT-cell receptorHematopoietic Stem Cell Transplantationmedicine.diseaseNKG2DKiller Cells NaturalLeukemia030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACytomegalovirus InfectionsImmunologybiology.proteinlcsh:RC581-607Hematopoietic stem cellsFrontiers in Immunology
researchProduct

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐ver…

2021

Sirolimus has emerged as an alternative to calcineurin inhibitors-based (CNI) graft-versus-host disease (GVHD) prophylaxis. This retrospective study compares the outcome of 133 consecutive adult patients with haematological malignancies undergoing haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF), combined with cyclosporine A (PTCy-CsA-MMF,

medicine.medical_specialtyHaploidentical transplantationCyclophosphamidebusiness.industryUrologyMycophenolatemedicine.diseaseTransplantationGraft-versus-host diseaseSirolimusToxicityMedicineStem cellbusinessmedicine.drugeJHaem
researchProduct

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotep…

2021

ABSTRACT One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impa…

medicine.medical_specialtyTransplantation ConditioningPredictive transplantation scoresCyclophosphamideAcute myelogenous leukemiaGraft vs Host DiseaseThioTEPAInternal medicinemedicineHumansImmunology and AllergyBusulfanCyclophosphamideTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationCell BiologyHematologyHaploidentical transplantation with TBF conditioningTacrolimusFludarabineTransplantationsurgical procedures operativeMolecular MedicinebusinessThiotepaVidarabineBusulfanmedicine.drugTransplantation and Cellular Therapy
researchProduct